PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement
Authors
Abou-Alfa, G. K.Borbath, I.
Goyal, L.
Lamarca, Angela
Macarulla, T.
Oh, D. Y.
Roychowdhury, S.
Sadeghi, S.
Shroff, R. T.
Li, A.
Soto, J.
Avogadri, F.
Dambkowski, C. L.
Javle, M. M.
Affiliation
Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY;Issue Date
2022
Metadata
Show full item recordCitation
Abou-Alfa GK, Borbath I, Goyal L, Lamarca A, Macarulla T, Oh DY, et al. PROOF 301: A multicenter, open-label, randomized, phase 3 trial of infigratinib versus gemcitabine plus cisplatin in patients with advanced cholangiocarcinoma with an FGFR2 gene fusion/rearrangement. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680304925.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.TPS4171Type
Meetings and Proceedingsae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.TPS4171